Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Migalastat→

Migalastat PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
108147-54-2
Molecular formula
C6H13NO4
Molecular weight
163.17 g/mol
Drug class
Pharmacological chaperonealpha-galactosidase A stabiliser for Fabry disease
Mechanism of action
Reversibly binds the active site of amenable mutant alpha-galactosidase A (alpha-Gal A), stabilising the enzyme and promoting trafficking to lysosomes, where it can catabolise globotriaosylceramide and related substrates. It is only suitable for GLA variants demonstrated to be amenable to migalastat.
Indications / reported uses
  • Treatment of adults with a confirmed diagnosis of Fabry disease and an amenable GLA variant based on the validated in-vitro amenability assay; not indicated for non-amenable variants or paediatric patients

Sources: US FDA prescribing information — GALAFOLD (migalastat) · EMA EPAR — Galafold · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Pharmacological chaperone; alpha-galactosidase A stabiliser for Fabry disease

Mechanism of action

Reversibly binds the active site of amenable mutant alpha-galactosidase A (alpha-Gal A), stabilising the enzyme and promoting trafficking to lysosomes, where it can catabolise globotriaosylceramide and related substrates. It is only suitable for GLA variants demonstrated to be amenable to migalastat.

General use cases

  • Treatment of adults with a confirmed diagnosis of Fabry disease and an amenable GLA variant based on the validated in-vitro amenability assay; not indicated for non-amenable variants or paediatric patients

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Migalastat PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Migalastat Permitted Daily Exposure (PDE) report (the Migalastat PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Migalastat Occupational Exposure Limit (OEL) report (the Migalastat OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.